IMA

Get to know Chaitan Khosla and the unique value of the Stanford IMA

Institute Scholar Peter Kim is accelerating the creation of new medicines and you give the world a different future.

Chemical engineer Chaitan Khosla explains why microbes make the best drug factories in the world — and why science is still playing catch-up.

The goal of the collaboration is to rapidly improve care for patients with tumors that form from hormone-releasing cells.

In a study led by Institute Scholar Peter Kim, a low-cost COVID-19 vaccine that does not require refrigeration provided immunity in rhesus monkeys for one year.

The collaboration will enable the development of medications to treat a type of brain cancer.

The IMA led by Chaitan Khosla has space in the building where their staff helps basic and applied researchers from schools of Medicine, Engineering and H&S prototype new medicines.

Deerfield Management Commits up to $130 Million to Support Stanford’s Innovative Translational Research

University photographer Andrew Brodhead takes us inside Stanford’s expanded Biosafety Level 3 (BSL3) lab.

At the Academic Council meeting, President Marc Tessier-Lavigne discussed how Stanford is pivoting its Long-Range Vision in light of COVID-19.

Stanford’s new IMA arose before the COVID-19 pandemic struck, but now its programs are focused entirely on helping faculty generate and test new medicines to slow the spread.

With leaders appointed for the Changing Human Experience, Public Humanities and Innovative Medicines Accelerator, those initiatives are poised to further humanities research.

At a recent Dean's Lecture Series, Dean Lloyd Minor discussed organizational culture and diversity with Emma Walmsley, CEO of GlaxoSmithKline.